RegentAtlantic Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

RegentAtlantic Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,495	Closed	-$262K	–	723
2022 Q1	$262K	Sell	2,495 -39	-2%	-$3.8K	0.01%	604
2021 Q4	$273K	Sell	2,534 -202	-7%	-$22K	0.01%	598
2021 Q3	$300K	Sell	2,736 -263	-9%	-$27.3K	0.01%	557
2021 Q2	$281K	Sell	2,999 -202	-6%	-$18.6K	0.01%	542
2021 Q1	$295K	Sell	3,201 -322	-9%	-$27.2K	0.01%	478
2020 Q4	$258K	Sell	3,523 -2,834	-45%	-$211K	0.01%	452
2020 Q3	$494K	Buy	+6,357	New	+$437K	0.02%	324

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RegentAtlantic Capital's HZNP Position: Q2 2022 in Review

RegentAtlantic Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 2,495 shares — an estimated $262K sold.

RegentAtlantic Capital first reported a position in HZNP in Q3 2020 and held it in 7 quarters. The position peaked at $494K in Q3 2020. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

RegentAtlantic Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
RegentAtlantic Capital sold 2,495 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $262K.
RegentAtlantic Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 7 quarters.
RegentAtlantic Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $494K in Q3 2020.
616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on RegentAtlantic Capital's 13F filing for Q2 2022, filed 15 Aug 2022.